GOVXW - GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference | Benzinga
Preclinical Data for GEO-CM02 Demonstrates Single-Dose Protection
Against Multiple SARS-CoV-2 Variants
ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen SARS-CoV-2 vaccine. The new unpublished data were presented during the Keystone Symposia on Molecular and Cellular Biology, Vaccinology During and After COVID-19, being held in Atlanta, Georgia on September 17-20, 2023.
| Presentation Details & Summary: |
| Abstract Title: |
| MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models |
| Abstract Authors: |
| Shannon Stone1, Amany Elsharkawy1, Janhavi Natekar1, Sreenivasa Rao Oruganti2, Mary Hauser2, Arban Domi2, Pratima Kumari2, Anchala Guglani1, Mark Newman2, and Mukesh Kumar1 |
| 1 Georgia State University 2 GeoVax Labs, Inc. |
| Presenting Author: |
| Shannon Stone, Georgia State University |
First-generation SARS-CoV-2 vaccines based on the spike (S) protein induce neutralizing antibodies provide significant levels of protection. However, vaccine efficacy is disrupted by emerging variants that contribute to neutralizing antibody evasion, requiring updating and booster doses. To address this limitation, GeoVax has designed multi-antigen SARS-CoV-2 vaccines based on the S, membrane (M), and envelope (E) proteins, which are designed to engage both the humoral (antibody) and cellular (T-cell) arms of the immune system and to broaden both the function and specificity. Efficacy of the vaccine, designated GEO-CM02, was tested using the industry standard, lethal hACE2 transgenic ...